US FDA Mum On Whether Woodcock Would Stick Around Long-Term For Califf
Woodcock’s willingness to stay on at US FDA for more than a transitional period after Robert Califf’s expected confirmation as commissioner may depend on exactly the type of authority and tasks he’d be willing to delegate to her. Plus, some other agency personnel updates.
You may also be interested in...
Julie Tierney will become CBER’s deputy director for strategy, policy and legislation, a newly created position.
When Comirnaty was approved in 2021, the product in the vials was identical, but the agency still had to state that legally they were different without confusing people.
Acting commissioner Janet Woodcock will remain at the agency and become principal deputy commissioner when Califf arrives.